Objectives: Patients with dementia due to Alzheimer's disease (AD) are often cared for by family members who experience physical, psychological, social, and financial burdens associated with provision of care. This study quantifies the impact of caregiving in Brazil and helps identify characteristics associated with caregiving. MethOds: Data were analyzed from the 2012 National Health and Wellness Survey (NHWS) in Brazil (n = 12,000), an Internet-based survey of adults (aged 18+), using stratified random sampling (by sex and age) to ensure demographic representation of the Brazil adult population. Caregivers were compared with non-caregivers on select comorbidities considered potential outcomes of caregiving, plus sociodemographic characteristics, health characteristics and behaviors, and Charlson comorbidity index (CCI) scores. Binary logistic regression models assessed comorbidities associated with caregiving, adjusting for potential confounds (CCI, age, gender, education, income, insurance, and marital status). Results: Among 10,853 respondents (caregivers [n= 209]; non-caregivers [n= 10,644]), caregivers were on average 42.1 years old, and 53% were female, 52% married/living with a partner, 87% insured, and 42% living with 1+ children in the household. Caregivers vs. non-caregivers were more frequently obese, smokers, insured, employed, and with college education or above, and they had higher CCI scores and higher income, all p < .05. Adjusting for covariates, caregiving was associated with significantly increased risk of depressive symptoms (odds ratio [OR] = 2.008), major depressive disorder (OR= 1.483), anxiety (OR= 1.714), insomnia (OR= 1.644), hypertension (OR= 1.584), pain (OR= 1.704), and diabetes (OR= 2.103), all p< .015. cOnclusiOns: This is the first study on caregivers for persons with dementia in Brazil using a large dataset (NHWS). Being a caregiver (compared with noncaregiver) is a predictor of overall psychiatric and clinical disorders in this sample. The online survey format provides certain sampling advantages but may under-represent caregivers without access/comfort with online technology. Direct treatment and policies to help caregivers are needed in Brazil. Objectives: Despite the existence of standardized medical criteria, clinical diagnosis of Alzheimer's disease remains difficult. Lack of diagnostic certainty or possible distress related to positive results could limit application of new testing technologies. Independent of the therapeutic value of prevention or cure, however, diagnostic information could have value in informing contingency planning or have intrinsic value: the value of "just knowing". This paper aims to quantify respondents' preferences for obtaining AD diagnostic tests and to estimate the perceived value of AD test information. MethOds: Discrete-choice experiment (DCE) and contingentvaluation (CV) questions were administered to N= 1301 respondents aged 60 years or older in Germany and the United Kingdom. 12 pairs of virtual AD diagnostic tests were presented (defined by test type, test precision defined by false-positive or falsenegative test results, and test cost) and a no-test alternative. DCE questions were based on a predetermined experimental design. A double-bounded, dichotomouschoice CV question was used to further elicit willingness to take an AD test and pay for it. Choice data of respondents interested in taking a test were analyzed using random-parameters logit. A probit model characterized respondents who were not willing to take a test. Results: Most respondents in both countries had a positive value for AD diagnostic test information. Most respondents who indicated an interest in testing in Germany (N= 631) and the UK (N= 670) preferred brain imaging without radioactive marker, followed by brain imaging with radioactive marker and then spinal tap. Diagnostic tests with better precision were preferred. German respondents had relatively greater heterogeneous preferences and lower moneyequivalent values for test features compared to UK respondents. cOnclusiOns: Respondents preferred less invasive diagnostic procedures and tests with higher accuracy. Diagnostic test accuracy was more important than test type. Respondents expressed a willingness to pay up to € 700 to receive a less invasive test with the highest accuracy. Objectives: The aim of this study was to understand the current impact of partial onset seizures (POS) on health outcomes and costs. MethOds: Patients were identified from the 2010 & 2013 5EU and 2011 -2012 Brazil National Health and Wellness Survey, a nationally represented, internet-based survey of adults (18+ years). Patients self-reported a diagnosis of epilepsy with POS and were categorized into ≥ 1 seizure per week, 1-3 seizures per month, 1-4 seizures per year, < 1 seizure per year (reference). Patients completed the SF-36v2 (mental (MCS), physical component summary (PCS)), SF-6D (health utility), Work Productivity and Activity Impairment Questionnaire and reported on resource utilization in the past six months. Costs were estimated from the literature. Generalized linear regression analyses were conducted controlling for covariates (e. g., age, gender, marital status, comorbidities, years diagnosed with epilepsy). Results: There were 175 patients in the 5EU and 32 in Brazil, 11.1% reported ≥ 1 seizures/week, 7.7% reported 1-3 seizures/month, 26.1% 1-4 seizures/year, and 55.1% < 1seizures/year. MCS, PCS, utilities, productivity categorized into three groups: placebo, PR-fampridine responders (those with a mean improvement from baseline in the 12-item MS walking scale of ≥ 8 points over 24 weeks), and PR-fampridine nonresponders (those with worsening, no change, or < 8 points improvement in MSWS-12). Changes from baseline were calculated for the EQ-5D utility index and visual analogue scale (VAS) by visit and over the 24 weeks. Within-group and pairwise comparisons were assessed based on the least square (LS) means using analysis of covariance (ANCOVA) models adjusting for baseline EQ-5D scores. Results: The placebo patients (n= 64), responders (n= 33), and nonresponders (n= 35) were similar in baseline age, race, weight, and number of relapses in the past 1 and 2 years. The responders had higher mean baseline EQ-5D utility (0.56 vs. 0.51 and 0.52, respectively) and VAS (62.9 vs. 59.1 and 60.5, respectively) scores than the placebo patients and nonresponders. Over the 24 weeks, the EQ-5D utility score improved in the responders (mean change: 0.06, 95% CI: [0.01, 0.12]) but worsened in the placebo patients (mean change: -0.03,95% CI: [-0.07, 0.01]) and nonresponders (mean change: -0.07,95% CI: [-0.12, -0.02] ). Similar trends were observed in the VAS scores although the differences within groups were generally not statistically significant. cOnclusiOns: PR-fampridine 10 mg tablets demonstrated significantly greater improvement in QoL among responders, despite starting from higher baseline EQ-5D scores, than the placebo or nonresponder groups. 
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